AKT MAPK - BioProject

Halofuginone sensitizes lung cancer organoids to cisplatin via suppressing PI3K/AKT and MAPK signaling pathways

Lung cancer is the leading reason for cancer fatality worldwide. In this research study, we found that HF hindered the spreading, generated G0/G1 phase arrest, and advertised apoptosis in lung cancer cells in a dose-dependent manner. Furthermore, combination of cisplatin and HF revealed that HF could animate the cisplatin-resistant patient-derived lung cancer cells organoids and lung cancer cells to cisplatin treatment. Taken together, this research recognized HF as cisplatin sensitizer and dual path inhibitor, which could offer new approach to boost prognosis of patients with cisplatin-resistant lung cancer cells.

Source link: https://www.ncbi.nlm.nih.gov/bioproject/769938

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions